Cattle material in OTCs
This article was originally published in The Tan Sheet
Executive SummaryAn FDA proposed rule would prohibit the use of certain cattle materials in drugs and homeopathics to prevent the spread of bovine spongiform encephalopathy, according to a Federal Register notice published Jan. 12. The list of materials prohibited from use includes items such as the brain, skull, eyes and spinal cord from cattle 30 months and older. The notice points out homeopathic preparations and OTCs approved through the monograph process will be required to comply with the rule, even though they have not been approved through a new drug application. "Although FDA's database of these products is incomplete, some of them may contain cattle materials that would be prohibited under this proposed rule. The requirements proposed...apply to all drugs for humans, including those marketed without an approved application," the notice states. Comments on the proposed rule are due by March 13...
You may also be interested in...
Eighteen years of free trade threatens to crash, as a result of the stalemate in the market access agreement between Switzerland and the EU. Industry association Swiss Medtech is advising local medtech manufacturers to find notified bodies and authorized representatives based in the EU. However, local company SQS remains confident of its ongoing notified body role.
With $1.3bn invested in over 200 high-tech start-ups, OurCrowd is now sharpening its focus on medtech. Medtech Insight spoke to founder Jon Medved to find out more.
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.